ArticleCureus2026
Assessing Mortality Prediction: Comparing the Effectiveness of the Fournier Gangrene Severity Index and the Uludag Index.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Fournier's gangrene (FG) is a fulminant necrotizing infection associated with substantial morbidity and high mortality. Early and accurate risk stratification is essential to guide clinical decision-making. The Fournier Gangrene Severity Index (FGSI) and the Uludag Fournier Gangrene Severity Index (UFGSI) are widely used prognostic tools; however, their comparative performance in Mexican populations remains insufficiently characterized. This study aimed to assess the association of FGSI and UFGSI with in-hospital mortality and to explore their comparative prognostic performance in a Mexican cohort. Methodology This retrospective cohort study was conducted at a tertiary-level public hospital in Mexico City. We included 65 adults with confirmed FG treated between July 2022 and February 2025. Clinical, demographic, and laboratory data were collected to calculate FGSI, UFGSI, and the Age-Adjusted Charlson Comorbidity Index. Survivors and non-survivors were compared using Student's t-test and chi-square tests, and associations with in-hospital mortality were evaluated using multivariate logistic regression with traditional and adjusted cutoff values. Statistical significance was defined as a p-value <0.05. Results Overall mortality was 18/65 (27.7%). Most patients were male (44/65, 67.7%), and the mean age was 59.4 ± 11 years. Non-survivors were older than survivors (64.8 ± 10 vs. 57.5 ± 11 years; p < 0.05). The most frequent etiology was proctologic origin (37/65, 56.9%). The most common comorbidity was diabetes (46/65, 70.8%), followed by systemic arterial hypertension (25/65, 38.5%). Mean index scores were higher among non-survivors than survivors for both FGSI (9.1 ± 4 vs. 5.8 ± 3; p = 0.002) and UFGSI (12.6 ± 5 vs. 8.4 ± 4; p = 0.001). Using traditional cutoff points, multivariate logistic regression demonstrated statistically significant associations with mortality for FGSI (odds ratio (OR) = 3.70; 95% confidence interval (CI) = 1.01-13.55; p = 0.048) and UFGSI (OR = 4.70; 95% CI = 1.26-17.44; p = 0.021). Conclusions FGSI and UFGSI were both associated with in-hospital mortality in FG. In this cohort, UFGSI showed a stronger association with in-hospital mortality using traditional cutoff values. Larger prospective studies are warranted to validate adjusted cutoff points across diverse clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.